219 related articles for article (PubMed ID: 31158500)
1. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Langer CJ; Redman MW; Wade JL; Aggarwal C; Bradley JD; Crawford J; Stella PJ; Knapp MH; Miao J; Minichiello K; Herbst RS; Kelly K; Gandara DR; Papadimitrakopoulou VA
J Thorac Oncol; 2019 Oct; 14(10):1839-1846. PubMed ID: 31158500
[TBL] [Abstract][Full Text] [Related]
2. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW; Papadimitrakopoulou VA; Minichiello K; Hirsch FR; Mack PC; Schwartz LH; Vokes E; Ramalingam S; Leighl N; Bradley J; Miao J; Moon J; Highleyman L; Miwa C; LeBlanc ML; Malik S; Miller VA; Sigal EV; Adam S; Wholley D; Sigman C; Smolich B; Blanke CD; Kelly K; Gandara DR; Herbst RS
Lancet Oncol; 2020 Dec; 21(12):1589-1601. PubMed ID: 33125909
[TBL] [Abstract][Full Text] [Related]
4. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
Jhaveri K; Chang MT; Juric D; Saura C; Gambardella V; Melnyk A; Patel MR; Ribrag V; Ma CX; Aljumaily R; Bedard PL; Sachdev JC; Dunn L; Won H; Bond J; Jones S; Savage HM; Scaltriti M; Wilson TR; Wei MC; Hyman DM
Clin Cancer Res; 2021 Jan; 27(2):447-459. PubMed ID: 33148674
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
6. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Edelman MJ; Redman MW; Albain KS; McGary EC; Rafique NM; Petro D; Waqar SN; Minichiello K; Miao J; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
J Thorac Oncol; 2019 Oct; 14(10):1853-1859. PubMed ID: 31302234
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract][Full Text] [Related]
8. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W
Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740
[TBL] [Abstract][Full Text] [Related]
10. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
Borghaei H; Redman MW; Kelly K; Waqar SN; Robert F; Kiefer GJ; Stella PJ; Minichiello K; Gandara DR; Herbst RS; Papadimitrakopoulou VA
Clin Lung Cancer; 2021 May; 22(3):178-186. PubMed ID: 33358401
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Dickler MN; Saura C; Richards DA; Krop IE; Cervantes A; Bedard PL; Patel MR; Pusztai L; Oliveira M; Cardenas AK; Cui N; Wilson TR; Stout TJ; Wei MC; Hsu JY; Baselga J
Clin Cancer Res; 2018 Sep; 24(18):4380-4387. PubMed ID: 29793946
[No Abstract] [Full Text] [Related]
12. Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Moore HM; Savage HM; O'Brien C; Zhou W; Sokol ES; Goldberg ME; Metcalfe C; Friedman LS; Lackner MR; Wilson TR
Mol Cancer Ther; 2020 Jan; 19(1):292-303. PubMed ID: 31534012
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
Owonikoko TK; Redman MW; Byers LA; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Al Baghdadi T; Lara P; Miao J; Kelly K; Ramalingam SS; Herbst RS; Papadimitrakopoulou V; Gandara DR
Clin Lung Cancer; 2021 May; 22(3):187-194.e1. PubMed ID: 33583720
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Leighl NB; Redman MW; Rizvi N; Hirsch FR; Mack PC; Schwartz LH; Wade JL; Irvin WJ; Reddy SC; Crawford J; Bradley JD; Stinchcombe TE; Ramalingam SS; Miao J; Minichiello K; Herbst RS; Papadimitrakopoulou VA; Kelly K; Gandara DR
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429332
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN; Redman MW; Arnold SM; Hirsch FR; Mack PC; Schwartz LH; Gandara DR; Stinchcombe TE; Leighl NB; Ramalingam SS; Tanna SH; Raddin RS; Minichiello K; Bradley JD; Kelly K; Herbst RS; Papadimitrakopoulou VA
Clin Lung Cancer; 2021 May; 22(3):170-177. PubMed ID: 33221175
[TBL] [Abstract][Full Text] [Related]
16. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
[TBL] [Abstract][Full Text] [Related]
17. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Juric D; Krop I; Ramanathan RK; Wilson TR; Ware JA; Sanabria Bohorquez SM; Savage HM; Sampath D; Salphati L; Lin RS; Jin H; Parmar H; Hsu JY; Von Hoff DD; Baselga J
Cancer Discov; 2017 Jul; 7(7):704-715. PubMed ID: 28331003
[TBL] [Abstract][Full Text] [Related]
18. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.
Tamura K; Kodaira M; Shimizu C; Yonemori K; Yunokawa M; Shimomura A; Kobayashi T; Nakano K; Tomomatsu J; Ito Y; Tanaka J; Kuriki H; Gu Z; Takahashi S
Cancer Sci; 2018 May; 109(5):1592-1601. PubMed ID: 29500843
[TBL] [Abstract][Full Text] [Related]
20. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
